Related Experiment Video
Updated: Apr 19, 2026

Catheter Ablation in Combination With Left Atrial Appendage Closure for Atrial Fibrillation
Published on: February 26, 2013
Statin therapy decreased the recurrence frequency of atrial fibrillation after electrical cardioversion: a
Peng Yan1, Pingshuan Dong1, Zhijuan Li1
1Department of Cardiology, First Affiliated Hospital, Henan Science and Technology University, Luoyang, Henan, China (mainland).
Insights
Statins significantly reduce atrial fibrillation (AF) recurrence after electrical cardioversion (EC). This meta-analysis confirms statin therapy, particularly atorvastatin and rosuvastatin, benefits patients by preventing AF relapse.
Area of Science:
- Cardiology
- Pharmacology
Background:
- Atrial fibrillation (AF) recurrence post-electrical cardioversion (EC) remains a clinical challenge.
- The role of statin agents in preventing AF relapse after EC is not well-defined.
Purpose of the Study:
- To evaluate the efficacy of statin agents in preventing AF recurrence following EC.
- To conduct a meta-analysis of randomized controlled trials (RCTs) assessing this clinical outcome.
Main Methods:
- Systematic literature search of major databases (Medline, EMBASE, Web of Science, Cochrane).
- Inclusion of RCTs comparing statin therapy versus placebo or conventional treatment in post-EC AF patients.
- Meta-analysis of pooled results presented as risk ratios (RRs) with 95% confidence intervals (CIs).
Main Results:
- Analysis of 5 RCTs involving 524 patients.
- Statins significantly decreased AF recurrence post-EC (RR=0.76, p=0.004).
- Beneficial effects observed with atorvastatin and rosuvastatin, particularly in younger patients (<65 years) and within 12 months post-EC.
Conclusions:
- Statin administration, specifically atorvastatin or rosuvastatin, is effective in reducing AF recurrence post-EC.
- Statins represent a beneficial therapeutic option for maintaining sinus rhythm after electrical cardioversion.
Background:
It is unclear whether statin agents provide clinical benefit in preventing the relapse of atrial fibrillation (AF) after electrical cardioversion (EC). The purpose of this study was to assess the effect of statin agents on the recurrence of AF after EC by conducting a meta-analysis of randomized controlled trials (RCTs).
Material And Methods:
We conducted a systematic literature search of Medline, EMBASE, ISI Web of Science, and Cochrane databases. RCTs comparing clinical endpoint of the recurrence of AF associated with statin administration vs. no statin treatment (placebo or conventional medical therapy) in patients with AF after EC were eligible. Combined results are presented as risk ratios (RRs) with 95% confidence intervals (CIs).
Results:
A total of 5 trials with 524 patients were available for analysis. The pooling analysis showed that statin agents significantly reduced the recurrence of AF after EC compared with no statin treatment (RR=0.76, 95% CI 0.63-0.92; p=0.004; I2=44%). The beneficial effect was shown both in AF subjects receiving atorvastatin or rosuvastatin treatment (atorvastatin 80 mg: RR=0.82, p=0.05; atorvastatin 10 mg: RR=0.27, p=0.03; rosuvastatin: RR=0.38, p=0.04) and in younger patients (<65 years; RR=0.58, p=0.0005). Furthermore, the benefit of statin agents on preventing AF recurrence after EC was demonstrated within 3-month follow-up (p=0.03), and the clinical benefit seemed likely to remain until no less than 12 months after EC (p=0.05).
Conclusions:
Based on the currently available data, administration of statin agents, especially atorvastatin or rosuvastatin, is beneficial in lowering the frequency of AF recurrence after EC.
Related Concept Videos
ECG Interpretation of Arrhythmias II: Atrial, Junctional and Ventricular Arrhythmias
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Atherosclerosis III: Management
Dysrhythmias VI: Management of Dysrhythmias

